Pembrolizumab
- Generic Name
- Pembrolizumab
- Brand Names
- Keytruda
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1374853-91-4
- Unique Ingredient Identifier
- DPT0O3T46P
- Background
Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 ...
- Indication
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
- Associated Conditions
- Advanced Endometrial Cancer, Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma (UC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Cervical Cancer, Metastatic Esophageal Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Triple Negative Breast Cancers, Metastatic Urothelial Carcinoma (UC), Metastatic cutaneous squamous cell carcinoma, Metastic Renal Cell Carcinoma, Non-Small Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage II, Persistent Cervical Cancer, Recurrent Cervical Cancer, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Renal Cell Carcinoma (RCC), Resectable Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Stage III Melanoma, Stage IIIA Non Small Cell Lung Cancer, Unresectable Melanoma, Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma, High risk, early Triple Negative Breast Cancer, High risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG, Locally advanced Adenocarcinomas of the Gastroesophageal Junction, Locally advanced Esophageal Carcinoma, Locally advanced Urothelial Carcinoma, Metastatic HER2-positive Adenocarcinoma of the Stomach, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic High Tumor Mutation Burden Solid Tumors, Metastatic Merkel Cell Carcinoma (MCC), Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Microsatellite Instability-High (MSI-H) Solid Tumors, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic Mismatch repair deficient (dMMR) solid tumors, Recurrent Cutaneous Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent, locally advanced Adenocarcinomas of the Gastroesophageal Junction, Recurrent, locally advanced Merkel Cell Carcinoma, Refractory Classical Hodgkin's Lymphoma, Relapsed Classical Hodgkin's Lymphoma, Stage 3 Non-Small Cell Lung Carcinoma (NSCLC), Unresectable High Tumor Mutation Burden Solid Tumors, Unresectable Microsatellite Instability High Colorectal Cancer, Unresectable Microsatellite Instability-High (MSI-H) Solid Tumors, Unresectable Mismatch Repair Deficient Colorectal Cancer, Unresectable Mismatch repair deficient (dMMR) solid tumors, Unresectable, locally advanced HER2-positive Adenocarcinoma of the Stomach, Unresectable, locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Unresectable, locally recurrent Triple Negative Breast Cancer, Unresectable, recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 100
- Registration Number
- NCT02546986
- Locations
- πΊπΈ
Palo Verde Hematology Oncology, Glendale, Arizona, United States
πΊπΈUCLA Hematology Oncology, Los Angeles, California, United States
πΊπΈUniversity Cancer and Blood Center, LLC, Athens, Georgia, United States
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
- Conditions
- Head and Neck Squamous Cell CarcinomaRecurrent Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaRecurrent Nasopharynx CarcinomaRecurrent Salivary Gland CarcinomaSquamous Cell Carcinoma Metastatic in the Neck With Occult PrimaryStage III Major Salivary Gland CarcinomaStage III Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage III Nasopharyngeal CarcinomaStage IV Nasopharyngeal CarcinomaStage IVA Major Salivary Gland Carcinoma
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT02538510
- Locations
- πΊπΈ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 141
- Registration Number
- NCT02528357
- Locations
- π³π±
GSK Investigational Site, Amsterdam, Netherlands
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-10-08
- Target Recruit Count
- 89
- Registration Number
- NCT02521844
- Locations
- πΊπΈ
University of Arizona Cancer Center, 3838 N. Campbell Avenue, RM 2111, Site 203, Tucson, Arizona, United States
πΈπ¬National University Hospital, 1E Kent Ridge Road, NUHS Tower Block, Level 7, Site 101, Singapore, Singapore
πΈπ¬National Cancer Centre Singapore, 11 Hospital Drive, Site 102, Singapore, Singapore
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Stage III Fallopian Tube Cancer AJCC v7Stage III Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIB Primary Peritoneal Cancer AJCC v7Stage IV Primary Peritoneal Cancer AJCC v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IIIC Primary Peritoneal Cancer AJCC v7
- Interventions
- First Posted Date
- 2015-08-11
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT02520154
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
πΊπΈMD Anderson in The Woodlands, The Woodlands, Texas, United States
πΊπΈMD Anderson in Sugar Land, Sugar Land, Texas, United States
Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Craig L Slingluff, Jr
- Target Recruit Count
- 22
- Registration Number
- NCT02515227
- Locations
- πΊπΈ
University of Virginia Cancer Center, Charlottesville, Virginia, United States
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT02513472
- Locations
- πΊπΈ
Facility #2, San Antonio, Texas, United States
πΊπΈFacility #1, Madison, Wisconsin, United States
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2019-07-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT02511184
- Locations
- πΊπΈ
City of Hope National Medical Center, Duarte, California, United States
πΊπΈEmory University Hospital, Atlanta, Georgia, United States
πΊπΈUniversity of Alabama at Birmingham, Birmingham, Alabama, United States
Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
- Conditions
- Interventions
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 127
- Registration Number
- NCT02509507
- Locations
- πΊπΈ
HonorHealth Research Institute, Scottsdale, Arizona, United States
πΊπΈUniversity of California Los Angeles, Santa Monica, California, United States
πΊπΈRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1301
- Registration Number
- NCT02506153
- Locations
- πΊπΈ
Illinois CancerCare-Macomb, Macomb, Illinois, United States
πΊπΈCarle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States
πΊπΈMcFarland Clinic - Ames, Ames, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.